The impact of serum uric acid on cardiovascular outcomes in the LIFE study [5]

Kidney International

Volumn 66, Issue 4, 2004, Pages 1714-1715

  Daskalopoulou, Stella S ^b   Athyros, Vasilios G ^b   Elisaf, Moses ^b   Mikhailidis, Dimitri ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; ATORVASTATIN; CREATININE; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; URIC ACID;

ARTERY DISEASE; CARDIOVASCULAR DISEASE; CLINICAL STUDY; CREATININE BLOOD LEVEL; DRUG ACTIVITY; DRUG MECHANISM; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LETTER; LIFE STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; URIC ACID BLOOD LEVEL; VASCULAR DISEASE;

EID: 4644293396     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.938_8.x     Document Type: Letter

References (5)

1. HOIEGGEN A, ALDERMAN MH, KJELDSEN SE, et al: LIFE Study Group: The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 65:1041-1049, 2004
2. ATHYROS VG, ELISAF M, PAPAGEORGIOU AA, et al: GREACE Study Collaborative Group: Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease. A subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis 43:589-599, 2004
3. YOUSSEF F, GUPTA P, SEIFALIAN AM, et al: The effect of short-term treatment with simvastatin on renal function in patients with peripheral arterial disease. Angiology 55:53-62, 2003
4. HEART PROTECTION STUDY COLLABORATIVE GROUP: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet 361:2005-2016, 2003
5. DASKALOPOULOU SS, MIKHAILIDIS DP, ATHYROS VG, et al: Fenofibrate and losartan. Ann Rheum Dis 63:469-470, 2004